Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2019 | SB8: a bevacizumab biosimilar for NSCLC

Martin Reck • 29 Sep 2019
ESMO 2019
Lung Cancer Non-Small Cell Lung Cancer Bevacizumab

Martin Reck, MD, PhD, German Center of Lung Research, Grosshansdorf, Germany, discusses a Phase III study comparing SB8, a proposed bevacizumab biosimilar, and reference bevacizumab in patients with metastatic or recurrent non-squamous Non-Small cell lung cancer (NSCLC). This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

More from Martin Reck

5:41
JAVELIN Lung100, PRIMUS, NintNivo, IMpower010: investigating IO in NSCLC
Martin Reck • 8 Aug 2022
2:35
Atezo maintenance therapy improves survival in the IMpower133 trial of ES-SCLC
Martin Reck • 1 Feb 2021
3:03
KEYNOTE-799: pembro + chemoradiotherapy in locally advanced NSCLC
Martin Reck • 1 Feb 2021
3:24
Pembro +/- ipi in metastatic NSCLC: KEYNOTE-598
Martin Reck • 1 Feb 2021

Related Videos

7:37
What is the optimal follow-up for lung cancer long term survivors?
Robert Rintoul • 19 Apr 2024
2:03
Biomarker detection for early cancer detection
Robert Rintoul • 19 Apr 2024
0:45
Assessing treatment options for lung cancer with interstitial lung disease
Matthew Hatton • 18 Apr 2024
1:47
Assessing follow-up strategies in post-surgical lung cancer: insights from a Phase III trial
Robert Rintoul • 19 Apr 2024
The content of VJOncology is intended for healthcare professionals